🔍

INDGN - Indegene

📊 NSE: INDGN 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 7:57

📢 Recent Corporate Announcements

Indegene Schedules Q4 and Annual FY26 Earnings Call for April 30, 2026

🟡 NEUTRAL ⭐ 4/10

EARNINGS 📅 22 Apr 2026, 11:38 AM

Indegene Limited has announced its earnings conference call to discuss the financial results for the fourth quarter and the full fiscal year ending March 31, 2026. The call is scheduled for Thursday, April 30, 2026, at 8:00 AM IST. Senior management, including CEO Manish Gupta and CFO Suhas Prabhu, will be present to interact with investors and analysts. This event is crucial for shareholders to understand the company's performance trajectory and future guidance following the FY26 close.

Earnings conference call scheduled for April 30, 2026, at 8:00 AM IST
Discussion to cover both Q4 FY26 and full-year FY26 financial performance
Key speakers include Chairman & CEO Manish Gupta and CFO Suhas Prabhu
Universal access dial-in numbers provided: +91 22 6280 1162 and +91 22 7115 8063
DiamondPass registration available for early participants to skip the queue

💡 Investors should mark their calendars for April 30 to listen to management's commentary on growth and margins. Review the audited financial results which will be released prior to the call for a detailed fundamental analysis.

Indegene Limited Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 03:35 PM

Indegene Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The filing confirms that all securities received for dematerialization during the quarter ended March 31, 2026, were processed and confirmed to the depositories. The Registrar and Share Transfer Agent, MUFG Intime India Private Limited, verified that security certificates were mutilated and cancelled as per regulatory requirements. This is a standard administrative disclosure required for all listed entities in India.

Compliance certificate submitted for the quarter ended March 31, 2026.
Confirmation provided by Registrar and Share Transfer Agent (RTA) MUFG Intime India Private Limited.
Reported zero requests for rematerialization of securities during the period.
All dematerialization requests were processed and records updated within prescribed SEBI timelines.

💡 No action is required as this is a routine regulatory filing. Investors should monitor the company's upcoming full-year financial results for material performance indicators.

Indegene UK Subsidiary Acquires Trilogy Writing Assets for GBP 190,679

🟡 NEUTRAL ⭐ 4/10

M&A 📅 01 Apr 2026, 06:04 PM

Indegene Limited's UK subsidiary has entered into a Trade and Asset Purchase Agreement to acquire the business operations of Trilogy Writing and Consulting Limited. This transaction follows Indegene's acquisition of 100% share capital of the seller in March 2026. The deal, valued at GBP 190,679, represents an internal consolidation of assets as a going concern. As both parties are wholly owned subsidiaries of Indegene, the transaction is classified as a related party transaction conducted at arm's length.

Indegene Healthcare UK Ltd to purchase trade and business assets from Trilogy Writing and Consulting Ltd
Total transaction value is GBP 190,679
Both entities are 100% indirectly owned subsidiaries of Indegene Limited
The acquisition is being executed as a going concern following a previous share purchase in March 2026

💡 This is a routine internal restructuring following a prior acquisition and has minimal financial impact on the consolidated entity. Investors should treat this as a procedural integration step and maintain their current outlook on the company.

Indegene Limited Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 27 Mar 2026, 11:43 AM

Indegene Limited has officially notified the stock exchanges regarding the closure of its trading window starting April 1, 2026. This action is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the finalization of financial results for the fiscal year ending March 31, 2026. The window will remain closed for all designated persons and their immediate relatives until 48 hours after the results are declared. This is a standard regulatory procedure and does not indicate any fundamental change in the company's operations.

Trading window closure effective from Wednesday, April 1, 2026.
Closure pertains to the finalization of financial results for the year ending March 31, 2026.
Trading window will reopen 48 hours after the dissemination of results to the BSE and NSE.
Restriction applies to all Designated Persons, their immediate relatives, and other insiders.

💡 No action is required as this is a routine regulatory filing; investors should monitor the company's future announcements for the specific date of the FY26 earnings release.

Indegene Limited Allots 93,390 Equity Shares Under RSU 2020 Plan

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 18 Mar 2026, 08:52 PM

Indegene Limited has announced the allotment of 93,390 equity shares on March 18, 2026, following the exercise of Restricted Stock Units (RSUs). The allotment was approved by the Board of Directors through a circular resolution under the company's RSU 2020 plan. These shares include categories both with and without bonus elements as per the plan's structure. This is a routine corporate action that results in a marginal increase in the company's total paid-up equity share capital.

Total allotment of 93,390 equity shares to eligible employees.
Shares issued under the RSU 2020 plan via circular resolution dated March 18, 2026.
Allotment covers RSUs both with and without bonus elements.
The new shares will rank pari-passu with the existing equity shares of the company.

💡 No action is required as this is a routine administrative allotment. Investors should note the minor dilution in equity which is typical for companies using stock-based compensation.

Indegene Limited to Meet Authum Investment on March 18, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 13 Mar 2026, 03:29 PM

Indegene Limited has scheduled a one-on-one in-person meeting with Authum Investment on March 18, 2026, in Bengaluru. This disclosure is made in compliance with SEBI Listing Obligations and Disclosure Requirements. The company has explicitly stated that no unpublished price sensitive information will be shared during this interaction. Such meetings are standard practice for maintaining investor relations and providing clarity on publicly available information.

One-on-one meeting scheduled with Authum Investment on March 18, 2026
The meeting will be conducted in-person at Bengaluru
Compliance filing under SEBI (LODR) Regulations, 2015
No unpublished price sensitive information (UPSI) to be shared during the meet

💡 No immediate action is required as this is a routine investor interaction. Investors should monitor the company's website for any new investor presentations that may be uploaded following the meeting.

Indegene CEO Manish Gupta Featured in Public Podcast on YouTube

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 12 Mar 2026, 02:35 PM

Indegene Limited has filed a disclosure under Regulation 30 regarding a public podcast featuring its CEO, Manish Gupta. The podcast, titled 'The Indegene Story', is available on YouTube and provides insights into the company's journey. The company has explicitly stated that no unpublished price sensitive information (UPSI) was shared during the conversation. This filing is a routine regulatory compliance measure for management media appearances.

CEO Manish Gupta featured in a YouTube podcast titled 'The Indegene Story' released on March 12, 2026.
The disclosure was made in compliance with Regulation 30 of SEBI (LODR) Regulations, 2015.
Company confirms that no unpublished price sensitive information (UPSI) was disclosed during the session.

💡 Investors may watch the podcast to gain qualitative insights into the company's history and leadership vision, but no immediate financial impact is expected from this disclosure.

Indegene to Acquire Two UK Entities for GBP 2.7 Million in Internal Restructuring

🟡 NEUTRAL ⭐ 6/10

M&A 📅 01 Mar 2026, 05:33 PM

Indegene Limited is streamlining its corporate structure by acquiring 100% equity in two UK-based subsidiaries, DT Associates Research and Consulting Services and Trilogy Writing and Consulting, for a combined cash consideration of approximately GBP 2.7 million. This internal restructuring will bring both entities under Indegene Healthcare UK Limited. DT UK reported FY25 revenue of GBP 6.4 million, while Trilogy UK reported GBP 2.34 million. The transaction is expected to be completed by March 31, 2026, and is classified as a related party transaction conducted at arm's length.

Acquisition of 100% stake in DT UK for GBP 2,001,000 and Trilogy UK for GBP 702,348
DT UK revenue declined to GBP 6.4 million in FY25 from GBP 9.2 million in FY24
Trilogy UK showed revenue growth, reaching GBP 2.34 million for the period ending March 2025
The move is primarily for internal restructuring to consolidate UK-based life science service operations
Total cash consideration for both acquisitions is approximately GBP 2.703 million

💡 Investors should view this as a routine corporate cleanup to simplify the subsidiary hierarchy. No immediate impact on consolidated financials is expected as the entities were already part of the group.

Indegene Limited Schedules Investor Meetings with Locus Investment Group and Buoyant Capital

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 25 Feb 2026, 07:00 PM

Indegene Limited has announced a schedule for one-on-one meetings with institutional investors in March 2026. The company is set to meet Locus Investment Group virtually on March 2nd and Buoyant Capital in person on March 5th in Bengaluru. These meetings are part of the company's regular engagement with the investment community to discuss business operations. The company has clarified that no unpublished price sensitive information will be shared during these interactions.

Virtual 1x1 meeting scheduled with Locus Investment Group on March 2, 2026.
In-person 1x1 meeting scheduled with Buoyant Capital on March 5, 2026, in Bengaluru.
The interactions are part of routine investor relations and disclosure requirements under SEBI regulations.
Company confirms that no unpublished price sensitive information (UPSI) will be disclosed.

💡 No immediate action is required as these are routine investor meetings. Investors may look for any subsequent corporate presentations or transcripts if released by the company.

Indegene Limited Allots 327,880 Equity Shares Under ESOP and RSU Plans

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 20 Feb 2026, 09:09 PM

Indegene Limited has announced the allotment of 327,880 equity shares following a board resolution passed by circulation on February 20, 2026. The allotment includes shares issued under both the ESOP 2020 and RSU 2020 plans, covering categories with and without bonus elements. This action is part of the company's ongoing employee incentive and retention strategy. While this results in a marginal increase in the total paid-up capital, it is a standard procedure for growth-oriented tech-service firms.

Total allotment of 327,880 equity shares to eligible employees.
Shares issued under the ESOP 2020 and RSU 2020 incentive schemes.
Allotment covers plans both with and without bonus elements.
Resolution passed by the Board of Directors via circulation on February 20, 2026.

💡 No action is required as this is a routine administrative allotment. Investors should treat this as a standard part of employee compensation that causes minor equity dilution.

Indegene Limited Schedules Series of Investor Meetings with Major Mutual Funds in Feb 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 16 Feb 2026, 04:51 PM

Indegene Limited has announced a comprehensive schedule for investor and analyst meetings spanning from February 19 to February 25, 2026. The company will engage in one-on-one meetings with prominent institutional investors including Nippon Mutual Fund, HDFC Mutual Fund, and HSBC Mutual Fund in Mumbai. Additionally, Indegene will participate in major industry events such as the IIFL 17th Entrepreneurial India Conference and Kotak's Chasing Growth 2026 conference. These meetings are intended to discuss business updates and strategy, though the company clarified that no unpublished price-sensitive information will be shared.

One-on-one meeting scheduled with DT Fund in Bangalore on February 19, 2026.
Multiple meetings with Nippon, HDFC, and HSBC Mutual Funds in Mumbai on February 23, 2026.
Participation in the IIFL 17th Entrepreneurial India Conference on February 24, 2026.
Attendance at the Kotak Institutional Equities: Chasing Growth 2026 conference on February 25, 2026.

💡 Investors should watch for any investor presentations or transcripts released following these meetings for insights into the company's growth trajectory. No immediate trading action is necessary as these are routine institutional interactions.

Indegene Schedules 1x1 Meetings with Fidelity, ICICI Pru, and Others on Feb 12-13

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 09 Feb 2026, 05:16 PM

Indegene Limited has announced a series of one-on-one meetings with prominent institutional investors scheduled for February 12 and 13, 2026. The company will engage with high-profile entities including Fidelity International, ICICI Prudential Mutual Fund, Abakkus Asset Manager, and ENAM Holdings. These in-person meetings in Mumbai are part of the company's regular investor relations outreach. While no unpublished price-sensitive information will be shared, the involvement of major funds indicates sustained institutional interest in the company.

Four one-on-one meetings scheduled with major institutional investors over a two-day period.
Meetings on February 12 include Abakkus Asset Manager, Fidelity International, and ENAM Holdings.
Meeting with ICICI Prudential Mutual Fund is scheduled for February 13, 2026.
All scheduled interactions are set to take place in person in Mumbai.

💡 No immediate action is required as these are routine investor meetings; however, investors should monitor for any new investor presentations uploaded to the exchanges.

Indegene Q3 FY26 Revenue Grows 30.8% YoY to INR 9,421 Mn; Large Deal Wins Boost Outlook

🟢 POSITIVE ⭐ 9/10

EARNINGS 📅 04 Feb 2026, 06:06 PM

Indegene reported a robust Q3 FY26 with total revenue of INR 9,421 million, a 30.8% YoY increase, including 18.3% organic growth. The company successfully integrated BioPharm and reported an adjusted EBITDA margin of 18.5%, with plans to reach 20% in 6-8 quarters. Significant deal wins were highlighted, including a $20 million TCV contract and a $10 million annual revenue engagement. Customer metrics improved with $1M+ accounts rising to 52 and revenue per employee exceeding $70,000.

Revenue increased 30.8% YoY to INR 9,421 million; organic growth was 18.3% YoY.
Adjusted EBITDA margin stood at 18.5%, up 30 bps QoQ despite acquisition-related costs.
Secured 7 large deals exceeding $1M ACV each, including a major $20M TCV biotech partnership.
$1M+ customer count grew by 12 to 52; active customers increased to 86.
Revenue per employee surpassed $70,000, driven by specialized AI-led platforms and domain expertise.

💡 Maintain a positive outlook given the strong deal pipeline and organic growth momentum. Watch for EBITDA margin expansion towards the 20% target as acquisition synergies and large deals scale.

Indegene Limited to Open Trading Window from February 1, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 29 Jan 2026, 07:15 PM

Indegene Limited has announced the opening of its trading window for designated persons starting February 1, 2026. This follows the completion of the approval and declaration process for the financial results for the quarter ended December 31, 2025. The notification is a standard compliance requirement under SEBI (Prohibition of Insider Trading) Regulations 2015. Designated persons and their immediate relatives are now permitted to trade in the company's equity shares until further notice.

Trading window for designated persons to officially open on February 1, 2026
Opening follows the declaration of financial results for the quarter ended December 31, 2025
Compliance maintained with SEBI Prohibition of Insider Trading Regulations 2015
Applies to all designated persons, their immediate relatives, and other insiders

💡 This is a routine regulatory filing with no impact on company fundamentals. Investors should focus on the actual financial performance reported for the December 2025 quarter.

Indegene Q3 Revenue Jumps 31% YoY to ₹9,421 Million; Completes ₹9,146 Million BioPharm Acquisition

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 29 Jan 2026, 07:02 PM

Indegene Limited reported a strong 30.8% YoY growth in revenue from operations, reaching ₹9,421 million for Q3 FY26. Net profit for the quarter stood at ₹1,029 million, showing stability despite the integration of the BioPharm acquisition which cost ₹9,146 million ($104 million). The company also announced the allotment of 13,332 equity shares under its RSU 2020 plan and reconstituted key board committees. The nine-month revenue for FY26 has reached ₹25,071 million, compared to ₹20,837 million in the previous year.

Revenue from operations grew 30.8% YoY to ₹9,421 million in Q3 FY26.
Completed acquisition of BioPharm Parent Holding Inc. for ₹9,146 million ($104 million) on October 1, 2025.
Consolidated net profit for the quarter recorded at ₹1,029 million with an EPS of ₹4.29.
Allotted 13,332 equity shares pursuant to the RSU 2020 Plan.
Nine-month total income reached ₹25,683 million, up from ₹21,653 million YoY.

💡 Investors should view the significant revenue growth and successful M&A integration as positive indicators of scale. Monitor the EBITDA margins in upcoming quarters to ensure the BioPharm acquisition is yielding the expected operational efficiencies.

View All INDGN Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Enterprise Commercial Solutions (60.6% of revenue) grew 26.2% YoY; Enterprise Medical Solutions (27.9% of revenue) grew 13.4% YoY; Brand Activation (7.9% of revenue) declined 20.0% YoY; Others (3.6% of revenue) grew 24.7% YoY.

Geographic Revenue Split

Over 96% of total revenue is generated from international markets, primarily North America and Europe.

Profitability Margins

PAT margin for FY 2024-25 was 14.3% (up from 13.0% in FY 2023-24). Q2 FY26 PAT margin was 12.7%, reflecting a 2.6% sequential reduction due to increased operational investments.

EBITDA Margin

Q2 FY26 EBITDA margin was 17.6%, down from 18.4% YoY and 20.2% in Q1 FY26. Management anticipates a near-term compression of 1.5% due to M&A and talent investments.

Capital Expenditure

Depreciation and amortization for FY 2024-25 was INR 80.2 Cr. Specific future Capex in INR Cr was not disclosed, though the company is investing heavily in talent and technology infrastructure.

Credit Rating & Borrowing

Finance costs for Q2 FY26 were INR 3.8 Cr, a 4.3% YoY decrease. Interest income fell 22.5% YoY to INR 18.4 Cr due to lower yields on investments in the US and India.

⚙️ Operational Drivers

Raw Materials

As a digital-first service provider, the primary 'raw material' is human capital. Employee benefit expenses represent 64.1% of total revenue (INR 515.8 Cr in Q2 FY26).

Import Sources

Talent is sourced globally, with major operational hubs in India, the United States, and the United Kingdom.

Key Suppliers

Not applicable for a service-based digital company; however, the company relies on technology vendors for its digital-first operating model.

Capacity Expansion

The company is investing in talent 'ahead of the curve' to support a growing deal pipeline. It recently acquired BioPharm (US) and WARN & Co. (UK) in October 2025 to expand consulting and medical capabilities.

Raw Material Costs

Employee benefit expenses grew 16.7% YoY to INR 515.8 Cr in Q2 FY26, driven by headcount increases and wage hikes implemented post-June.

Manufacturing Efficiency

Efficiency is measured by revenue per employee, which management describes as 'market leading' due to high-value digital service delivery.

📈 Strategic Growth

Expected Growth Rate

17.10%

Growth Strategy

Growth is driven by a 9-14% CAGR in the life sciences outsourcing market. Strategy includes scaling the Enterprise Commercial segment (26.2% YoY growth), integrating AI into healthcare delivery, and executing M&A like BioPharm and WARN & Co. to accelerate growth over 6-8 quarters.

Products & Services

Omnichannel commercialization services, medical affairs solutions, regulatory consulting, and digital marketing for life sciences companies.

Brand Portfolio

Indegene, BioPharm, WARN & Co.

New Products/Services

AI-integrated commercialization platforms and advanced transformation consulting services via the WARN & Co. acquisition.

Market Expansion

Focusing on mid-sized pharmaceutical companies beyond the top 20 global biopharma and expanding presence in the UK and US markets.

Market Share & Ranking

Ranked 432nd among the top 500 listed entities in India based on average market capitalization in its first year of listing.

Strategic Alliances

Acquired BioPharm (US-based boutique firm) and WARN & Co. (UK-based consulting firm) in October 2025.

🌍 External Factors

Industry Trends

Increasing digital and tech adoption in pharma; outsourcing operations across verticals are expected to grow at a 9-14% CAGR through 2026.

Competitive Landscape

Competes with global consulting firms and specialized life sciences service providers in a highly regulated market.

Competitive Moat

Durable advantage through deep healthcare domain expertise and a digital-first operating model that is difficult for generic IT firms to replicate.

Macro Economic Sensitivity

Sensitive to global interest rates; interest income declined 22.5% due to reducing Fed and repo rates affecting investment yields.

Consumer Behavior

Shift toward omnichannel and digital engagement by pharma companies to reach healthcare providers more efficiently.

Geopolitical Risks

US administration actions on drug pricing and potential tariff announcements create policy uncertainty for the biopharma industry.

⚖️ Regulatory & Governance

Industry Regulations

Operations are impacted by US healthcare regulations (IRA, MFN negotiations) and global pharmaceutical compliance standards for medical and commercial data.